Active-ingredient Dossier

Insulin Aspart

Active-ingredient Dossier for Insulin Aspart (rapid acting insulin). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: FIASP
Brand: NOVORAPID
Brand: RYZODEG
Therapeutic area: Endocrinology

What is

Insulin Aspart Insulin aspart is a rapid acting insulin.

Australian brands containing

Insulin Aspart — FIASP — NOVORAPID — RYZODEG — NOVOMIX

Therapeutic areas

Insulin aspart is registered in endocrinology, with four brands marketed in this therapeutic area.

Sponsor landscape

Novo Nordisk Pharmaceuticals is the sponsor marketing insulin aspart in Australia.

PBS and regulatory activity

Two brands containing insulin aspart have PBS-listed items, with the latest PBS schedule date of 1 May 2026. Government expenditure for insulin aspart products reached AUD 57.2 million in the 2017–18 financial year, based on 274,219 scripts. Three brands have PBAC outcomes on record, with the latest outcome dated 1 July 2023. Two brands have AusPARs on record, with the latest dated 11 March 2020.